Juvaris gets infusion for infectious disease vaccines
Juvaris BioTherapeutics, a Burlingame, Calif.-based developer of vaccines to treat infectious diseases, announced that it raised financing toward its targeted $25 million second round of funding from SV Life Sciences and Kleiner Perkins Caufield & Byers. The company wouldn’t put a finer point on the amount, mostly because it is open to further investments in the round.
The money will give Juvaris a two-year runway to improve the immune responses caused by its vaccines. Right now, it is working on preventative treatments for the flu, as well as the herpes simplex virus type 2. It previously brought in $12 million in a first round of funding from Kleiner Perkins.
Next Story: Oorja nabs $500K for methanol fuel cells
Previous Story: With EPIX MegaPlex, movie studios will offer 3,000 movies on demand
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.